Delving into the Latest Updates on FY-103 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

FY 103, FY103

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertension

Inactive Indication-

Originator Organization

Beijing Foyou Pharma Co., Ltd.

Active Organization

Beijing Foyou Pharma Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的（1）评价FY103注射液单次给药在中国参与者中的安全性和耐受性。次要目的（1）评价FY103注射液单次给药在中国参与者中的药代动力学特征；（2）评价FY103注射液单次给药在中国参与者中的药效动力学特征；（3）评价FY103注射液单次给药在中国参与者中的免疫原性。

[Translation]

Primary Objectives: (1) To evaluate the safety and tolerability of a single dose of FY103 injection in Chinese participants. Secondary Objectives: (1) To evaluate the pharmacokinetic characteristics of a single dose of FY103 injection in Chinese participants; (2) To evaluate the pharmacodynamic characteristics of a single dose of FY103 injection in Chinese participants; (3) To evaluate the immunogenicity of a single dose of FY103 injection in Chinese participants.

Start Date-

Sponsor / Collaborator

Beijing Foyou Pharma Co., Ltd.

100 Clinical Results associated with FY-103

Login to view more data

100 Translational Medicine associated with FY-103

Login to view more data

100 Patents (Medical) associated with FY-103

Login to view more data

100 Deals associated with FY-103

Login to view more data